^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI-1206

    i
    Other names: BI-1206, BI1206, BI 1206, 6G 11
    Associations

    News

    Trials
    Company:
    BioInvent, CASI
    Drug class:
    Fcγ receptor IIB antagonist
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study of BI-1206 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (KEYNOTE-A04) (clinicaltrials.gov)
    P1/2, N=197, Recruiting, BioInvent International AB | N=90 --> 197 | Trial completion date: Jan 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • BI-1206
    1year
    17-BI-1206-02: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL (clinicaltrials.gov)
    P1/2, N=140, Recruiting, BioInvent International AB | N=98 --> 140 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CRP (C-reactive protein)
    |
    Calquence (acalabrutinib) • Rituxan Hycela (rituximab/hyaluronidase) • BI-1206
    1year
    A Competition-Based Strategy for the Isolation of an Anti-Idiotypic Blocking Module and Fine-Tuning for Conditional Activation of a Therapeutic Antibody. (PubMed, Biotechnol J)
    This strategy was used to isolate a scFv masking unit for the therapeutic antibody 6G11 (BI-1206), which is currently in clinical trials for the treatment of B-cell lymphoma to block the inhibitory Fcγ receptor IIB (CD32b)...The substitution of one key amino acid in the masking scFv reduced the affinity toward the 6G11 paratope by factor 10 but still mediated 9800-fold blocking of receptor binding. Proteolytic demasking allowed full recovery of therapeutic antibody function in vitro, supporting the concept of conditional antibody activation using this anti-idiotypic binding module.
    Journal
    |
    MMP9 (Matrix metallopeptidase 9)
    |
    BI-1206
    2years
    A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04) (clinicaltrials.gov)
    P1/2, N=90, Recruiting, BioInvent International AB
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • BI-1206
    3years
    A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=98, Recruiting, BioInvent International AB | N=30 --> 98 | Trial completion date: Dec 2023 --> Sep 2025 | Trial primary completion date: Mar 2023 --> Sep 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • BI-1206
    3years
    A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04) (clinicaltrials.gov)
    P1/2, N=90, Recruiting, BioInvent International AB | Enrolling by invitation --> Recruiting
    Enrollment status • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • BI-1206
    3years
    A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04) (clinicaltrials.gov)
    P1/2, N=90, Enrolling by invitation, BioInvent International AB | Recruiting --> Enrolling by invitation | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment status • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • BI-1206
    over4years
    A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04) (clinicaltrials.gov)
    P1/2, N=90, Recruiting, BioInvent International AB | Trial primary completion date: May 2024 --> Nov 2024
    Clinical • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • BI-1206
    over5years
    BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia (clinicaltrials.gov)
    P1/2, N=14, Completed, Cancer Research UK | Recruiting --> Completed | N=81 --> 14 | Trial completion date: Jan 2022 --> Mar 2020 | Trial primary completion date: Jan 2022 --> Mar 2020
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • BI-1206
    over5years
    A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, BioInvent International AB | Trial completion date: Jun 2020 --> Dec 2023 | Trial primary completion date: Jun 2020 --> Mar 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • BI-1206
    over5years
    A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04) (clinicaltrials.gov)
    P1/2, N=90, Recruiting, BioInvent International AB | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • BI-1206